Final 15-year results in premenopausal HR-positive early breast cancer: in SOFT, breast cancer-free interval was 78.6% with exemestane+OFS, 75.7% tamoxifen+OFS, 72.1% tamoxifen alone (HR 0.82 T+OFS vs T). Survival gains limited to high-risk subgroups.
RCTn = 5,707
Francis et al. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer